TG Therapeutics Dividend
Dividend criteria checks 0/6
TG Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | US$0.088 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25
TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe
Feb 08TG Therapeutics: Double Down On Partial Clinical Hold Non-Issue
Jan 28TG Therapeutics: Elucidating The Upcoming Binary Event
Dec 27Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TGTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TGTX's dividend payments have been increasing.
Dividend Yield vs Market
| TG Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (TGTX) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.9% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (TGTX) | 0% |
Notable Dividend: Unable to evaluate TGTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TGTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TGTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TGTX has not reported any payouts.